Cosmos HealthCOSM +12.43%29 Debt-to-Equity is 0.88 as of Mar. 2026, which is 300% above its 10-year median of 0.22. GuruFocus rates COSM with a GF Score™ of 29/100 and a GF Value™ of $0.36 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 97 Medical Distribution companies, Cosmos Health ranks worse than 73.2% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Cosmos Health's Debt-to-Equity or its related term are showing as below:
COSM'
s Debt-to-Equity Range Over the Past 10 Years
Min: -10.21 Med: 0.22 Max: 72.2
Current: 0.88
During the past 13 years, the highest Debt-to-Equity Ratio of Cosmos Health was 72.20. The lowest was -10.21. And the median was 0.22.
COSM's Debt-to-Equity is ranked worse than 73.2% of 97
companies
in the Medical Distribution industry
Industry Median: 0.48
vs COSM: 0.88
Cosmos Health (NAS:COSM) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cosmos Health Debt-to-Equity Related Terms
Cosmos Health Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Cosmos Health's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cosmos Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmos Health Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cosmos Health's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Cosmos Health's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmos Health (COSM) has a Debt-to-Equity of 0.88 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cosmos Health and its competitors. This is 300% above median its historical median of 0.22. According to the industry distribution chart, Cosmos Health ranks #71 out of 97 companies in the Medical Distribution industry, placing it in the top 73.2%.
Is Cosmos Health's Debt-to-Equity too high?
Cosmos Health's current Debt-to-Equity of 0.88 is 300% above median its 10-year median of 0.22. The Medical Distribution industry median Debt-to-Equity is 0.48. Cosmos Health's value of 0.88 is 83.3% above this industry median. Based on the distribution chart, Cosmos Health ranks #71 out of 97 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Cosmos Health has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosmos Health's Debt-to-Equity compare to HKPD and SNYR?
According to the Medical Distribution industry distribution chart, Cosmos Health ranks #71 out of 97 companies for Debt-to-Equity. This places Cosmos Health in the lower half of its industry. The industry median Debt-to-Equity is 0.48. Cosmos Health's value of 0.88 is 83.3% above this benchmark. While the company's 10-year median is 0.22 vs. the industry median of 0.48, Cosmos Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.48, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmos Health's current Debt-to-Equity of 0.88 is 83.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cosmos Health and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmos Health's current Debt-to-Equity is 0.88, which is 300% above median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmos Health stock overvalued right now?
Based on GuruFocus' analysis, Cosmos Health (COSM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.36, compared to a current price of $0.29 — trading 18.7% below its estimated fair value. The current Debt-to-Equity is 0.88, which is 300% above median its 10-year median of 0.22 and 83.3% above the Medical Distribution industry median of 0.48. Cosmos Health's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cosmos Health (COSM), the current Debt-to-Equity is 0.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmos Health (COSM) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmos Health stock appears to be undervalued.
The current stock price of $0.29 is trading 18.7% below its estimated GF Value™ of $0.36.
GuruFocus considers Cosmos Health to be Modestly Undervalued.
Key valuation signals for COSM:
Debt-to-Equity: 0.88 (300% above median its 10-year median of 0.22)
GF Value™: $0.36 vs. price of $0.29 (18.7% below fair value)
Industry Position: 83.3% above the Medical Distribution median (#71 of 97)
No single metric tells the full story. See the COSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
29GF Score
Get the complete analysis for COSM
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COSM has been successfully added to your 
